Cannara Biotech Stock Price, News & Analysis

Cannara Biotech (OTCQB:LOVFF) reported record-breaking financial results for Q3 2025, with total revenues reaching $27.3 million, a 40% increase year-over-year. The company achieved its seventeenth consecutive quarter of positive Adjusted EBITDA, which rose 173% to $7.6 million.

Key highlights include a 110% increase in gross profit to $12.1 million, improved gross margins of 44% (up from 29%), and record operating cash flow of $13.9 million. The company achieved a significant 26% yield improvement across its facilities, increasing annual capacity from 39,500 kg to 50,000 kg, meeting its Fiscal 2026 target ahead of schedule.

Additionally, Cannara secured approval for 5 SKUs in Quebec's upcoming vape category launch, representing 20% of all accepted in-store SKUs, and reduced its BMO credit facility interest rate to below 6%.

[ "Record revenue of $27.3M, up 40% year-over-year", "Gross profit increased 110% to $12.1M with margins expanding to 44%", "Record Adjusted EBITDA of $7.6M, up 173% year-over-year", "26% yield improvement achieved without additional capital expenditures", "Operating cash flow increased 221% to $13.9M", "Secured 20% market share in Quebec's new vape category", "Credit facility interest rate reduced to below 6%", "Earnings per share increased to $0.05 from $0.02 year-over-year" ]

Cannara Biotech (OTCQB: LOVFF) has secured preliminary acceptance from SQDC for 5 vape cartridge products to be distributed across all Québec retail stores starting November 2025. The company's products will represent 20% of the 25 vape cartridge SKUs planned for in-store distribution by year-end.

The company, which operates two mega facilities in Québec totaling over 1,650,000 sq. ft., will introduce both live resin and live rosin vape cartridges. This launch marks Québec's entry into the vape cartridge market, with significant potential given that the SQDC reported $741.5 million in revenue for 2024. Market research indicates 25% of Québec consumers used vapes in the past year, with vape segments representing approximately 15% of total sales in other major Canadian provinces.

Cannara Biotech Inc. (OTCQB: LOVFF), a vertically integrated cannabis producer with two mega facilities in Québec totaling over 1,650,000 sq. ft., has scheduled its fiscal Q3 2025 earnings release for July 28, 2025.

The financial results for the quarter ended May 31, 2025, will be released at 7:00 a.m. ET, followed by an earnings webcast at 11:00 a.m. ET. CFO Nicholas Sosiak will host the webcast, which will include prepared remarks and a Q&A session. Investors can submit questions in advance via email to investors@cannara.ca.

Cannara Biotech (LOVFF), a vertically integrated premium cannabis producer with two mega facilities in Québec totaling over 1,650,000 sq. ft, has announced an upcoming investor webcast scheduled for June 25, 2025, at 2:00 PM ET. During the presentation, CFO Nicholas Sosiak will discuss key aspects of Cannara's business operations, followed by an interactive Q&A session with investors. The webcast will be accessible through a pre-registration link, and an archived version will be available on the company's investor relations website.

Cannara Biotech (LOVFF) has achieved significant recognition and financial milestones in June 2025. The company won two prestigious awards at the 6th Annual Grow Up Awards Gala, with its Tribal brand securing Brand of the Year and Nugz Happle winning Accessory of the Year. On the financial front, Cannara has successfully reduced its cost of debt through two key actions: a $1 million partial repayment of the Olymbec convertible debenture and a 50 basis point reduction in the interest rate spread on its BMO Credit Facility, bringing overall debt costs below 6%. The company operates two mega facilities in Quebec totaling over 1,650,000 sq. ft., focusing on premium-grade cannabis production at competitive prices.

Cannara Biotech (LOVFF) reported strong Q2 2025 financial results, with net revenues reaching $26.6 million, a 35% increase from Q2 2024. The company achieved record profitability with gross profit before fair value adjustments rising 52% to $10.8 million and improved gross margins of 41%.

The company delivered its sixteenth consecutive quarter of positive Adjusted EBITDA, more than doubling to $7.1 million. National market share increased to 3.9%, with notable gains in Quebec (12.8%), Ontario (2.9%), and Alberta (2.7%). Net income reached $3.3 million, compared to a loss of $3.4 million in Q2 2024.

Operationally, Cannara is expanding its cultivation capacity with two new grow zones being activated in April and May 2025, bringing total active grow zones to 12 and expanding active canopy to over 300,000 sq. ft., supporting annual production capacity of up to 40,000 kg.

Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF), a vertically integrated premium cannabis producer with two mega facilities in Québec totaling over 1,650,000 sq. ft., has scheduled its fiscal Q2 2025 financial results announcement for April 28, 2025 at 7:00 a.m. ET.

The company will host an earnings webcast on April 29, 2025, at 11:00 a.m. ET, featuring CFO Nicholas Sosiak. The session will include prepared remarks and a Q&A segment. Investors can access the webcast through the company's website and submit questions in advance via email to investors@cannara.ca.

Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) has appointed Justin Cohen as an independent director to its Board and Audit Committee member. Cohen brings extensive experience in brand development, sales, and marketing from his roles at various companies.

As former Chief Marketing and Chief Commercial Officer at Psycho Bunny, Cohen led a tenfold revenue increase over three years through retail expansion and digital acceleration. His experience includes leadership positions at Keurig Dr Pepper, Google, ALDO Group, and Sony Music. Currently, he serves as a senior executive at Cosmetic Physician Partners, overseeing marketing across 55+ U.S. clinics.

The appointment aligns with Cannara's strategy to position its three flagship brands – Tribal, Nugz, and Orchid CBD – as leading cannabis brands in Canada. The company operates two mega facilities in Québec spanning over 1,650,000 sq. ft.

Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) has announced its participation in the Ventum Capital Markets Canadian Cannabis Conference on March 12th, 2025, at 1:40PM-2:00pm EST. The company's CEO Zohar Krivorot and CFO Nicholas Sosiak will deliver a presentation and engage with investors.

As a vertically integrated premium-grade cannabis producer, Cannara operates two mega facilities in Québec covering over 1,650,000 sq. ft. The presentation will highlight the company's:

• Impressive financial performance
• Rapid market share growth
• Cost advantages through Québec operations
• Efficient scaling while maintaining strong margins

The company stands out as one of Canada's fastest-growing and most profitable cannabis producers, maintaining profitability while others in the industry face challenges.